CA3099266A1 - Compositions and methods for reducing progression of nephrolithiasis - Google Patents

Compositions and methods for reducing progression of nephrolithiasis Download PDF

Info

Publication number
CA3099266A1
CA3099266A1 CA3099266A CA3099266A CA3099266A1 CA 3099266 A1 CA3099266 A1 CA 3099266A1 CA 3099266 A CA3099266 A CA 3099266A CA 3099266 A CA3099266 A CA 3099266A CA 3099266 A1 CA3099266 A1 CA 3099266A1
Authority
CA
Canada
Prior art keywords
polypeptide
enpp1
soluble
seq
nephrolithiasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099266A
Other languages
English (en)
French (fr)
Inventor
Demetrios Braddock
Clemens BERGWITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CA3099266A1 publication Critical patent/CA3099266A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3099266A 2018-05-08 2019-05-07 Compositions and methods for reducing progression of nephrolithiasis Pending CA3099266A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668293P 2018-05-08 2018-05-08
US62/668,293 2018-05-08
PCT/US2019/031049 WO2019217373A1 (en) 2018-05-08 2019-05-07 Compositions and methods for reducing progression of nephrolithiasis

Publications (1)

Publication Number Publication Date
CA3099266A1 true CA3099266A1 (en) 2019-11-14

Family

ID=68466827

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099266A Pending CA3099266A1 (en) 2018-05-08 2019-05-07 Compositions and methods for reducing progression of nephrolithiasis

Country Status (6)

Country Link
US (1) US12157903B2 (https=)
EP (1) EP3790628A4 (https=)
JP (1) JP2021523139A (https=)
AU (1) AU2019267545A1 (https=)
CA (1) CA3099266A1 (https=)
WO (1) WO2019217373A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
CN120383683A (zh) 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
KR20230048480A (ko) * 2020-05-27 2023-04-11 이노자임 파마, 인코포레이티드 말초 동맥 질환을 치료하기 위한 조성물 및 방법
KR20230047334A (ko) * 2020-05-27 2023-04-07 이노자임 파마, 인코포레이티드 혈관 평활근 세포 증식을 억제하기 위한 조성물 및 방법
WO2021252549A1 (en) * 2020-06-09 2021-12-16 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
CA3246877A1 (en) * 2022-03-30 2023-10-05 Yale University METHOD AND COMPOSITIONS FOR THE TREATMENT, ALLEVIATION AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH)
KR102748577B1 (ko) * 2022-07-19 2025-01-06 가천대학교 산학협력단 바이오마커 enpp7의 당뇨병의 진단 및 치료 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04292169A (ja) 1991-03-19 1992-10-16 Sekisui Chem Co Ltd ハイブリッド型人工膵臓
WO1995019570A1 (en) 1994-01-14 1995-07-20 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
JP4200100B2 (ja) 2001-11-07 2008-12-24 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質
US9055984B2 (en) 2004-04-21 2015-06-16 DePuy Synthes Products, Inc. Sternal reconstruction system
JP5199077B2 (ja) * 2005-06-10 2013-05-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
WO2008105911A2 (en) 2006-08-02 2008-09-04 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and methods of use
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EA201301082A1 (ru) 2011-03-29 2014-01-30 Бета-Селл Нв Способ изготовления инкапсулированных терапевтических продуктов и их применение
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
EP2970940B1 (en) * 2013-03-14 2018-07-25 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
BR112016006071B1 (pt) 2013-09-19 2021-12-28 Universitãtsspital Basel Enxerto vascular artificial e método para a produção de um enxerto vascular artificial
EP3967755B1 (en) * 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
EP4414028A3 (en) 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
JP6543119B2 (ja) 2015-07-10 2019-07-10 有限会社Ptmc研究所 ステントグラフト
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CA3032467A1 (en) * 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US20180085492A1 (en) 2016-09-29 2018-03-29 Northwestern University Antioxidant scaffolds for beta cell delivery

Also Published As

Publication number Publication date
EP3790628A1 (en) 2021-03-17
JP2021523139A (ja) 2021-09-02
AU2019267545A1 (en) 2020-11-26
US20210363506A1 (en) 2021-11-25
WO2019217373A1 (en) 2019-11-14
US12157903B2 (en) 2024-12-03
EP3790628A4 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
CA3099266A1 (en) Compositions and methods for reducing progression of nephrolithiasis
AU2022235636B2 (en) Compositions for treating pathological calcification conditions, and methods using same
JP5844459B2 (ja) 組換えヒトイズロン酸−２−スルファターゼを含む組成物および製剤ならびにその調製方法
US12234489B2 (en) Compositions for treating ectopic calcification disorders, and methods using same
JP2022130626A (ja) 小児鎌状赤血球貧血患者における脳卒中予防のための組成物および方法
KR20170129275A (ko) 재조합 인간 이듀로네이트 2-술파타아제의 제조 방법
JP2025000736A (ja) Ｅｎｐｐ１ポリペプチドおよびその使用方法
JPS6339585A (ja) 遺伝子操作による因子ＸＩＩＩａの製造
KR20250114034A (ko) Iga 프로테아제 폴리펩타이드 제제
HK1252797B (en) Compositions for treating pathological calcification conditions, and methods using same

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251022

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251222